Amphiregulin and epiregulin expression in colorectal carcinoma and the correlation with clinicopathological characteristics
- PMID: 20631481
- DOI: 10.1159/000315380
Amphiregulin and epiregulin expression in colorectal carcinoma and the correlation with clinicopathological characteristics
Abstract
Background: Amphiregulin (AREG) and epiregulin (EREG) have been found to play pivotal roles in several malignancies. However, the correlation between their expression and clinicopathological factors in colorectal carcinoma (CRC) is yet to be further investigated. To clarify the clinical significance of AREG and EREG expression in CRC, we detected serum and tissue levels of AREG and EREG.
Patients and methods: We detected serum AREG and EREG levels by ELISA, and tissue levels by immunohistochemical test in 73 patients with CRC. The correlation between each independent clinicopathological characteristic and AREG and EREG levels was examined.
Results: There was significant correlation between serum AREG level and vascular invasion. There was no correlation between EREG serum level and any clinicopathological characteristics. Among the 73 primary lesions, 51 were AREG-positive, and 48 were EREG-positive. AREG-positive status was significantly correlated with depth of tumor invasion, distant metastases, and nerve invasion. EREG-positive status was significantly correlated with depth of tumor invasion and distant metastases. Coexpression analysis showed that 46 patients were both AREG-positive and EREG-positive.
Conclusions: High serum and tissue levels of AREG and high tissue level of EREG are predictors of a poor prognosis in patients with CRC.
Copyright 2010 S. Karger AG, Basel.
Similar articles
-
Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases.BMC Cancer. 2012 Mar 13;12:88. doi: 10.1186/1471-2407-12-88. BMC Cancer. 2012. PMID: 22409860 Free PMC article.
-
Podoplanin expression identified in stromal fibroblasts as a favorable prognostic marker in patients with colorectal carcinoma.Oncology. 2009;77(1):53-62. doi: 10.1159/000226112. Epub 2009 Jun 25. Oncology. 2009. PMID: 19556810
-
Amphiregulin is a prognostic factor in colorectal cancer.Anticancer Res. 2012 Jun;32(6):2315-21. Anticancer Res. 2012. PMID: 22641668
-
Amphiregulin/epiregulin mRNA Expression and Primary Tumor Location in Colorectal Cancer.Anticancer Res. 2019 Sep;39(9):4729-4736. doi: 10.21873/anticanres.13655. Anticancer Res. 2019. PMID: 31519572
-
Prognostic value of amphiregulin and epiregulin mRNA expression in metastatic colorectal cancer patients.Oncotarget. 2016 Aug 23;7(34):55890-55899. doi: 10.18632/oncotarget.10151. Oncotarget. 2016. PMID: 27344184 Free PMC article. Review.
Cited by
-
Significance of Amphiregulin (AREG) for the Outcome of Low and High Grade Astrocytoma Patients.J Cancer. 2019 Feb 23;10(6):1479-1488. doi: 10.7150/jca.29282. eCollection 2019. J Cancer. 2019. PMID: 31031857 Free PMC article.
-
Epiregulin as a therapeutic target in non-small-cell lung cancer.Lung Cancer (Auckl). 2015 Oct 12;6:91-98. doi: 10.2147/LCTT.S60427. eCollection 2015. Lung Cancer (Auckl). 2015. PMID: 28210154 Free PMC article. Review.
-
Epiregulin Promotes Lung Metastasis of Salivary Adenoid Cystic Carcinoma.Theranostics. 2017 Aug 23;7(15):3700-3714. doi: 10.7150/thno.19712. eCollection 2017. Theranostics. 2017. PMID: 29109770 Free PMC article.
-
Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer.Sci Rep. 2021 Dec 10;11(1):23803. doi: 10.1038/s41598-021-03197-9. Sci Rep. 2021. PMID: 34893673 Free PMC article.
-
Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer.Oncotarget. 2019 Mar 1;10(18):1704-1715. doi: 10.18632/oncotarget.26722. eCollection 2019 Mar 1. Oncotarget. 2019. PMID: 30899442 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
